| Clinical data | |
|---|---|
| AHFS/Drugs.com | Consumer Drug Information |
| Routes of administration | Subcutaneous |
Sources edit
Yeah, I really do just list my sources first while developing an article
- Long-Term Efficacy and Safety of Recombinant Human Hyaluronidase (rHuPH20)- Facilitated Subcutaneous Infusion of Immunoglobulin G (IgG) (HyQvia; IGHy) in Patients with Primary Immunodeficiencies (PI) [1]
- Tolerability and Pharmacokinetic Properties of Ondansetron Administered Subcutaneously With Recombinant Human Hyaluronidase in Minipigs and Healthy Volunteers - it involves minipigs! [2]
- Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency[3]
- Pharmaceutical Approval Update [4]
- Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration (antibody info) [5]
- Human Immunoglobulin 10 % with Recombinant Human Hyaluronidase: Replacement Therapy in Patients with Primary Immunodeficiency Disorders (this one requires EBSCO) [6]
- ^ Wasserman, Richard L.; Stein, Mark R.; Melamed, Isaac; Kobrynski, Lisa J.; Gupta, Sudhir; Puck, Jennifer M.; Rubinstein, Arye; Engl, Werner; McCoy, Barbara; Leibl, Heinz; Yel, Leman (February 2015). "Long-Term Efficacy and Safety of Recombinant Human Hyaluronidase (rHuPH20)- Facilitated Subcutaneous Infusion of Immunoglobulin G (IgG) (HyQvia; IGHy) in Patients with Primary Immunodeficiencies (PI)". Journal of Allergy and Clinical Immunology. 135 (2): AB96. doi:10.1016/j.jaci.2014.12.1247.
{{cite journal}}:|access-date=requires|url=(help) - ^ Dychter, Samuel S.; Harrigan, Rena; Bahn, Jesse D.; Printz, Marie A.; Sugarman, Barry J.; DeNoia, Emanuel; Haughey, David B.; Fellows, Daniel; Maneval, Daniel C. (February 2014). "Tolerability and Pharmacokinetic Properties of Ondansetron Administered Subcutaneously With Recombinant Human Hyaluronidase in Minipigs and Healthy Volunteers". Clinical Therapeutics. 36 (2): 211–224. doi:10.1016/j.clinthera.2013.12.013.
- ^ Wasserman, Richard L.; Melamed, Isaac; Stein, Mark R.; Gupta, Sudhir; Puck, Jennifer; Engl, Werner; Leibl, Heinz; McCoy, Barbara; Empson, Victoria G.; Gelmont, David; Schiff, Richard I. (October 2012). "Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency". Journal of Allergy and Clinical Immunology. 130 (4): 951–957.e11. doi:10.1016/j.jaci.2012.06.021.
{{cite journal}}:|access-date=requires|url=(help) - ^ Gohil K (2014). "Pharmaceutical approval update". P T. 39 (11): 746–72. PMC 4218669. PMID 25395816.
- ^ Rosengren, Sanna; Dychter, Samuel S.; Printz, Marie A.; Huang, Lei; Schiff, Richard I.; Schwarz, Hans-Peter; McVey, John K.; Drake, Fred H.; Maneval, Dan C.; Kennard, Don A.; Frost, Gregory I.; Sugarman, Barry J.; Muchmore, Douglas B. (13 May 2015). "Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration". The AAPS Journal. 17 (5): 1144–1156. doi:10.1208/s12248-015-9782-0.
{{cite journal}}:|access-date=requires|url=(help) - ^ Sanford, Mark (13 June 2014). "Human Immunoglobulin 10 % with Recombinant Human Hyaluronidase: Replacement Therapy in Patients with Primary Immunodeficiency Disorders". BioDrugs. 28 (4): 411–420. doi:10.1007/s40259-014-0104-3.
{{cite journal}}:|access-date=requires|url=(help); no-break space character in|title=at position 24 (help)
Medical use edit
Inflammation edit
Other uses edit
Dosage edit
Adverse effects edit
Contraindications edit
Skin edit
Other adverse effects edit
Interactions edit
Chemical properties edit
Mechanism of action edit
Additional mechanisms edit
Pharmacokinetics edit
History edit
References edit
<references/